$4.12 +0.08 (2.00%)

SOPHiA GENETICS SA Ordinary Shares (SOPH)

SOPHiA GENETICS SA is a global leader in data-driven medicine, specializing in using artificial intelligence and computational biology to analyze complex healthcare data. The company provides a cloud-based platform that enables healthcare professionals and researchers to share, analyze, and interpret genomic and clinical data for improved diagnosis, treatment, and research in precision medicine. Founded in Switzerland, SOPHiA GENETICS aims to advance healthcare through collaborative data sharing and innovative technology.

🚫 SOPHiA GENETICS SA Ordinary Shares does not pay dividends

Company News

Artificial Intelligence in Diagnostics Market to hit USD 7.3 billion by 2032, says Global Market Insights Inc.
GlobeNewswire Inc. • Global Market Insights Inc. • October 7, 2024

The artificial intelligence in diagnostics market is projected to grow at a CAGR of 22.2% from 2024 to 2032, driven by the rising prevalence of chronic diseases and the increasing demand for AI tools in disease diagnosis.

Why Nvidia Stock Investors Should Be Excited About an Upcoming IPO
The Motley Fool • [email protected] (Jose Najarro) • May 30, 2024

CoreWeave, a company backed by Nvidia, is preparing to go public in 2025.

Wall Street Analysts Think SOPHiA GENETICS (SOPH) Could Surge 64.95%: Read This Before Placing a Bet
Zacks Investment Research • Zacks Equity Research • May 7, 2024

The average of price targets set by Wall Street analysts indicates a potential upside of 65% in SOPHiA GENETICS (SOPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga • Avi Kapoor • March 6, 2024

Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results. United Natural Foods posted adjusted earnings of 7 cents per share, compared to market estimates for a loss of 1 cent per share. The company’s quarterly sales came in at $7.78 billion, versus expectations of $7.87 billi...

Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky
MarketWatch • MarketWatch • December 28, 2023

Investors should consider this list of healthcare stocks for 2024